Cork, Michael, Diamant Tha?i, Lawrence Eichenfield, Peter Arkwright, Zhen Chen, Mohamed Kamal, John O’Malley, and Ashish Bansal. “Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years With Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and Then in a Subsequent Phase 3 Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s104. Accessed July 4, 2024. https://jofskin.org/33014/index.php/skin/article/view/1100.